Summary
We will develop a novel vaccine with broad efficacy against nontypeable Haemophilus influenzae (NTHi) strains following influenza A virus (IAV) infection. NTHi is one of the most common pathogens that cause secondary bacterial pneumonia following IAV infection. Although vaccines are available for IAV, they confer very limited protection against viral and bacterial co-infection, and effective vaccines against NTHi remain needed. NTHi vaccines under development focus on antibody responses that target bacterial surface proteins and lipooligosaccharide antigens, which are hindered by genetic and a
